Drugmaker Mylan's woes get worse with president engulfed in vast probe
He is one of those accused of colluding in conspiracy to prop up prices
San Francisco
MYLAN NV's latest troubles couldn't come at a worse time.
Two years ago, Mylan was a swaggering drugmaker on the way up, buying up rivals as it grew and diversified.
Then it faced political scrutiny over price hikes for its EpiPen allergy shot and increasing pressure on prices for the generic drugs that are the company's backbone.
In August, Mylan cut its 2018 outlook, and on Tuesday came another blow: its N…
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Cordlife’s independent auditor to retire after issuing disclaimer of opinion on FY2023 financials
Cordlife customers push for legal action
France's Casino supermarket chain to axe up to 3,200 jobs
Prada outshines rivals with 16% revenue lift boosted by Miu Miu
Toymaker Hasbro posts quarterly profit beat, slower sales decline
Hilton lifts 2024 profit forecast on international travel demand